Nigella sativa oil attenuates aluminum-induced behavioral changes, oxidative stress and cortico-hippocampal neuronal degeneration in rats

Background: Aluminum (AlCl3) usage in both the industrial and domestic arena has dramatically risen over time owing to its ubiquity and utility for many activities despite frequent reporting of its neurotoxic effects over wide range of concentrations. The neuro-protective effects of Nigella sativa Oil (NSO) following intermediate exposure to aluminum salts has largely been unexplored. The present study explores the ameliorative and neuro-protective functions of NSO on aluminum chloride (AlCl3)-induced damages in the frontal cortices and hippocampus of exposed rats. Methods: The study involved the use of thirty two adult male Wistar rats weighing 180 ± 20 g, randomly divided into four groups, in which group 1 received saline, group 2 received AlCl3 (100 mg/kg), group 3 received AlCl3 (100 mg/kg) followed by NSO (1 ml/kg) 30 min later, while group 4 received NSO (1 ml/kg) only. All administrations were done orally for 14 days. Standardized behavioural tests for anxiety and cognitive performance were carried on after the treatments prior to euthanizing (Ketamine 10 mg/kg, ip). On day 15, the rats were euthanized, and their brains excised, with the frontal cortex and hippocampus removed. Five of these samples were homogenized and centrifuged to analyze nitric oxide (NO) metabolites and total reactive oxygen species (ROS), and the other three were processed for histology (cresyl violet stain) and proliferative markers (Ki-67 immunohistochemistry). Results: Increased Transfer latency, time in dark box, escape latency and reduced rearing frequency, percentage alternation and time in platform quadrant were observed in the AlCl3 exposed rats. There was also an increased level of ROS and NO in the brain regions with marked inhibition of neuronal cell proliferation as evidenced by reduced Ki-67 protein expression in the brain of AlCl3 only rats. However, rats co-administered AlCl3 and NSO showed significantly reduced ROS and NO levels, improved anxiety-like and cognitive behaviors and increased Ki-67 expression when compared with AlCl3 only treated rats. Conclusion: AlCl3 exposure causes neuronal damage and impaired anxiety-like and memory indices which are associated with increased free radical generation and inhibited neuronal proliferation, whereas the antioxidant and neuro-protective properties of NSO were efficacious against the observed effects. Keywords: Aluminum chloride, memory impairment, neuronal damage, Ki-67, nigella sativa oi

2017 American Heart Association Focused Update on Pediatric Basic Life Support and Cardiopulmonary Resuscitation Quality: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

This focused update to the American Heart Association guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care follows the Pediatric Task Force of the International Liaison Committee on Resuscitation evidence review. It aligns with the International Liaison Committee on Resuscitation's continuous evidence review process, and updates are published when the International Liaison Committee on Resuscitation completes a literature review based on new science. This update provides the evidence review and treatment recommendation for chest compression-only CPR versus CPR using chest compressions with rescue breaths for children <18 years of age. Four large database studies were available for review, including 2 published after the "2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care." Two demonstrated worse 30-day outcomes with chest compression-only CPR for children 1 through 18 years of age, whereas 2 studies documented no difference between chest compression-only CPR and CPR using chest compressions with rescue breaths. When the results were analyzed for infants <1 year of age, CPR using chest compressions with rescue breaths was better than no CPR but was no different from chest compression-only CPR in 1 study, whereas another study observed no differences among chest compression-only CPR, CPR using chest compressions with rescue breaths, and no CPR. CPR using chest compressions with rescue breaths should be provided for infants and children in cardiac arrest. If bystanders are unwilling or unable to deliver rescue breaths, we recommend that rescuers provide chest compressions for infants and children

Mechanical characteristics of groundnut shell particle reinforced polylactide nano fibre

ABSTRACT The PLA-groundnut shell solution is electrospun to produce nanocomposite fibre. The spinneret containing the composite solution was placed 24.7 cm away from the aluminium collector, tilted at an angle of 30 °, and the solution flow rate kept at 1 mL/min. Groundnut Shell particle (GSP) weight fraction used was varied from 3 - 8 wt. %. Particle reinforced nanofibres were formed on the collector from the composite solution at 26 kV. These nanofibres were subjected to tensile test and the result indicates that at 6 wt. % untreated GSP reinforced fibre possessed the best tensile stiffness of 24.62 MPa. This corresponds to 2.201 % increase in Modulus of Elasticity over the unreinforced PLA (1.07 MPa). The 7 wt. % treated GSP fibre showed the least stiffness (0.33 MPa), which is 69 % reduction over that of unreinforced fibre. PLA fibre reinforced with 5 wt. % untreated GSP displayed best blend of properties over the unreinforced with increase of 286 % (4.43 x 10-4 HB), 1,502 % (1.07 MPa), 286 % (0.22 MPa), 6.8 % (0.05 J) and 1,081 % (~ 0.15 MPa) in hardness, stiffness, UTS, energy at break and stress at break respectively. However, ductility decreased by ~33.3 % when compared to the unreinforced (18.27). The 5 wt. % untreated GSP PLA reinforced fibre showed the highest UTS (0.855 MPa). The micrographs showed beads on reinforced fibres, while the virgin PLA showed no beads

Increasing importance of anthelmintic resistance in European livestock: creation and meta-analysis of an open database

Trabajo presentado al: COMBAR meeting (Combatting Anthelmintic Resistance in Ruminants). Atenas (Grecia). Febrero. 2022

The <i>Ectocarpus</i> genome and the independent evolution of multicellularity in brown algae

Brown algae (Phaeophyceae) are complex photosynthetic organisms with a very different evolutionary history to green plants, to which they are only distantly related1. These seaweeds are the dominant species in rocky coastal ecosystems and they exhibit many interesting adaptations to these, often harsh, environments. Brown algae are also one of only a small number of eukaryotic lineages that have evolved complex multicellularity (Fig. 1).We report the 214 million base pair (Mbp) genome sequence of the filamentous seaweed Ectocarpus siliculosus (Dillwyn) Lyngbye, a model organism for brown algae, closely related to the kelps (Fig. 1). Genome features such as the presence of an extended set of light-harvesting and pigment biosynthesis genes and new metabolic processes such as halide metabolism help explain the ability of this organism to cope with the highly variable tidal environment. The evolution of multicellularity in this lineage is correlated with the presence of a rich array of signal transduction genes. Of particular interest is the presence of a family of receptor kinases, as the independent evolution of related molecules has been linked with the emergence of multicellularity in both the animal and green plant lineages. The Ectocarpus genome sequence represents an important step towards developing this organism as a model species, providing the possibility to combine genomic and genetic2 approaches to explore these and other aspects of brown algal biology further

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca